We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

95 hedge funds and large institutions have $998M invested in G1 Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 18 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 18

35% more capital invested

Capital invested by funds: $741M → $998M (+$258M)

1% more funds holding

Funds holding: 94 → 95 (+1)

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
95
Holders Change
+1
Holders Change %
+1.06%
% of All Funds
2.17%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
21
Increased
44
Reduced
18
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$50.7M
2
State Street
State Street
Massachusetts
+$30.9M
3
Capital World Investors
Capital World Investors
California
+$23.1M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$19M
5
BlackRock
BlackRock
New York
+$17.5M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$24.5M
2
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$10.2M
3
EA
Emerald Advisers
Pennsylvania
-$8.4M
4
GTC
Ghost Tree Capital
New York
-$5.56M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
51
Squarepoint
New York
$795K +$784K +18,300 New
VEA
52
Virtus ETF Advisers
New York
$787K -$858K -20,022 -53%
CS
53
Credit Suisse
Switzerland
$744K +$396K +9,244 +117%
ProShare Advisors
54
ProShare Advisors
Maryland
$714K +$66.6K +1,554 +10%
Manulife (Manufacturers Life Insurance)
55
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$674K +$202K +4,707 +44%
S
56
SignatureFD
Georgia
$659K +$650K +15,162 New
Two Sigma Advisers
57
Two Sigma Advisers
New York
$617K +$608K +14,200 New
PA
58
Perceptive Advisors
New York
$611K +$602K +14,055 New
AIG
59
American International Group
New York
$578K +$199K +4,655 +54%
TRSOTSOK
60
Teachers Retirement System of the State of Kentucky
Kentucky
$544K +$99.4K +2,320 +23%
DekaBank Deutsche Girozentrale
61
DekaBank Deutsche Girozentrale
Germany
$504K – – –
AQR Capital Management
62
AQR Capital Management
Connecticut
$464K +$457K +10,670 New
WMSA
63
Weiss Multi-Strategy Advisers
New York
$435K +$428K +10,000 New
SG Americas Securities
64
SG Americas Securities
New York
$424K +$418K +9,758 New
MIM
65
MetLife Investment Management
New Jersey
$420K +$134K +3,123 +48%
Wells Fargo
66
Wells Fargo
California
$419K +$175K +4,080 +73%
AFM
67
Abbot Financial Management
Massachusetts
$382K +$12.9K +300 +4%
HCM
68
Hodges Capital Management
Texas
$320K – – –
State Board of Administration of Florida Retirement System
69
State Board of Administration of Florida Retirement System
Florida
$317K +$313K +7,301 New
MLICM
70
Metropolitan Life Insurance Company (MetLife)
New York
$296K +$95.3K +2,224 +48%
Balyasny Asset Management
71
Balyasny Asset Management
Illinois
$285K +$281K +6,554 New
SO
72
STRS Ohio
Ohio
$178K +$77.1K +1,800 +78%
Barclays
73
Barclays
United Kingdom
$159K +$13.7K +319 +10%
LTFS
74
Ladenburg Thalmann Financial Services
Florida
$144K – – –
Legal & General Group
75
Legal & General Group
United Kingdom
$141K +$37K +863 +36%
1 2
3
4 5

GTHX Hedge Fund Activity: Q2 2018 in Review

95 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2018, worth a combined $998M — up 35% from $741M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new GTHX positions and 20 closed out — a net gain of 1 holder — while 44 added to existing stakes and 18 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $50.7M. The largest seller was Boxer Capital, exiting entirely with an estimated $24.5M sold.

  • 95 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2018, up from 94 in Q1 2018.
  • Funds reported $998M of G1 Therapeutics, Inc. Common Stock stock for Q2 2018, up 35% quarter-over-quarter.
  • 21 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2018 and 20 closed out, a net change of +1 holder.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2018 was Bank of New York Mellon, an estimated $50.7M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2018 was Boxer Capital, an estimated $24.5M sold.

Based on aggregated 13F filings for Q2 2018.